-
RGS10 deficiency facilitates distant metastasis by inducing epithelial–mesenchymal transition in breast cancer
19 Apr 2024 18:11 GMT
… EMT in non-small cell lung cancer by RGS6 (Wang et al … can alter sensitivity to paclitaxel, cisplatin, and vincristine (Cacan et al … EMT, and sensitized cells to cisplatin treatment (Cai et al., 2020 …
-
Shilpa Medicare updates on launch of Pemetrexed Injection, 100mg/10 ml, 500 mg/50 ml, 1000 mg/100 ml
19 Apr 2024 18:06 GMT
… treatment of non-small cell lung cancer in combination with other chemotherapy … of mesothelioma in combination with cisplatin. PEMRYDI RTU® is a novel …
-
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
11 Apr 2024 16:52 GMT
… for non-small-cell lung cancer (NSCLC) patients ineligible … ,7,8 of all lung cancers cases, with nearly 60% … small-cell lung cancer: a cost-effectiveness analysis. Translational Lung Cancer Res. … -utility analysis of gemcitabine, cisplatin, and S-1 as …
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
05 Apr 2024 11:50 GMT
… lung cancer (ES-SCLC).
IMFINZI, in combination with gemcitabine and cisplatin … .
Notes
Small cell lung cancer
Lung cancer is the leading cause … IMFINZI in liver and lung cancers, the combination of … /lung-cancer-101/types-of-lung-cancer. Accessed …
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
05 Apr 2024 11:27 GMT
… lung cancer (ES-SCLC).
IMFINZI, in combination with gemcitabine and cisplatin … .
Notes
Small cell lung cancer
Lung cancer is the leading cause … IMFINZI in liver and lung cancers, the combination of … /lung-cancer-101/types-of-lung-cancer. Accessed …
-
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
04 Apr 2024 11:01 GMT
… non-small cell lung cancers (adenocarcinoma). Despite … been challenging.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … combination with platinum (cisplatin or carboplatin) …
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 11:00 GMT
… patients with metastatic lung cancer, lung cancer continues to … cycles.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … combination with platinum (cisplatin or carboplatin) …
-
Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management
25 Mar 2024 15:22 GMT
… guidelines for managing small cell lung cancer (SCLC) with systemic therapy, which … of carboplatin plus etoposide or cisplatin plus atezolizumab or durvalumab followed … . Systemic therapy for small-cell lung cancer: ASCO-Ontario Health (Cancer Care …
-
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
25 Mar 2024 11:00 GMT
… 1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350].
… on Day 1 or Cisplatin 75 mg/m2 … of extensive-stage small-cell Lung cancer (CASPIAN): a randomised, … for Extensive-Stage Small-Cell Lung Cancer. Clinicaltrials.gov identifier: NCT05745350 …
-
AstraZeneca's Tagrisso with the addition of chemotherapy showed favourable trend in OS in EGFR─mutated advanced lung cancer with further follow up in FLAURA2 phase III trial
23 Mar 2024 05:50 GMT
… the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) and … patients with advanced EGFR-mutated lung cancer, particularly the encouraging trend toward … (pemetrexed (500mg/m2) plus cisplatin (75mg/m2) or carboplatin …